Literature DB >> 18712323

[Possibilities and limits for treating psoriasis with biologics. Case reports].

A Süss1, A Colsman, J C Simon, M Sticherling.   

Abstract

The availability of biologics for the therapy of psoriasis has radically changed the options for systemic therapy of this disease. Their use is often coupled with a variety of restrictions--as a rule they are to be used as a 'last-line' therapy. The status of previous systemic therapy as a basic requirement for the use of biologics is analyzed and simultaneously, the possibilities of the physician to use the indication spectrum of biologics for the benefit of the patient are demonstrated by case reports.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18712323     DOI: 10.1007/s00105-008-1571-6

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  14 in total

1.  [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].

Authors:  Ulrich Mrowietz; Joachim Barth; Wolf-Henning Boehncke; Thomas Rosenbach; Gottfried Wozel
Journal:  J Dtsch Dermatol Ges       Date:  2005-06       Impact factor: 5.584

2.  Biologics in psoriasis: a quick reference guide.

Authors:  Valencia D Thomas; F Clarissa Yang; Joseph C Kvedar
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

3.  [Therapy of psoriasis vulgaris with efalizumab].

Authors:  Ulrich Mrowietz; Joachim Barth; Wolf-Henning Boehncke; Kristian Reich; Thomas Rosenbach; Volker Streit; Gottfried Wozel
Journal:  J Dtsch Dermatol Ges       Date:  2006-06       Impact factor: 5.584

4.  [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab].

Authors:  Ulrich Mrowietz; Joachim Barth; Wolf-Henning Boehncke; Kristian Reich; Thomas Rosenbach; Volker Streit; Gottfried Wozel
Journal:  J Dtsch Dermatol Ges       Date:  2006-05       Impact factor: 5.584

5.  Successful treatment of Von Zumbusch pustular psoriasis with infliximab.

Authors:  Jennifer T Trent; Francisco A Kerdel
Journal:  J Cutan Med Surg       Date:  2004 Jul-Aug       Impact factor: 2.092

Review 6.  [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].

Authors:  G Wozel
Journal:  Hautarzt       Date:  2005-09       Impact factor: 0.751

7.  Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.

Authors:  Oliver Schöffski; Matthias Augustin; Jörg Prinz; Karin Rauner; Erich Schubert; Stefan Sohn; Kristian Reich
Journal:  J Dtsch Dermatol Ges       Date:  2007-03       Impact factor: 5.584

8.  Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.

Authors:  S Benoit; A Toksoy; E-B Bröcker; R Gillitzer; M Goebeler
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

9.  Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

Authors:  Alexander Nast; Ina B Kopp; Matthias Augustin; Kirstin-Benita Banditt; Wolf-Henning Boehncke; Markus Follmann; Markus Friedrich; Matthias Huber; Christina Kahl; Joachim Klaus; Joachim Koza; Inga Kreiselmaier; Johannes Mohr; Ulrich Mrowietz; Hans-Michael Ockenfels; Hans-Dieter Orzechowski; Jörg Prinz; Kristian Reich; Thomas Rosenbach; Stefanie Rosumeck; Martin Schlaeger; Gerhard Schmid-Ott; Michael Sebastian; Volker Streit; Tobias Weberschock; Berthold Rzany
Journal:  J Dtsch Dermatol Ges       Date:  2007-07       Impact factor: 5.584

10.  Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.

Authors:  Rotraut Mössner; Diamant Thaci; Johannes Mohr; Sylvie Pätzold; Hans Peter Bertsch; Ullrich Krüger; Kristian Reich
Journal:  Arch Dermatol Res       Date:  2008-02-01       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.